Cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and cytochrome P450 (CYP) 4A-mediated arachidonic acid (AA) metabolism play an essential role in human inflammatory disorders. Blocking COX-2 pathway would shunt AA metabolism to the other pathway, thereby decreasing the efficacy and exacerbating adverse effects. Here we demonstrated that reprogramming COX-2, 5-LOX, and CYP4A-mediated AA metabolism in macrophages by salidroside (Sal) ameliorates monosodium urate (MSU) crystal-induced inflammation. Compared with COX-2 inhibitor celecoxib, Sal (80 mg/kg) presented a superior anti-arthritic profile in MSU crystal-treated rats, accompanied with the decreased expression of COX-2, 5-LOX, and CYP4A and production of prostaglandin E2 (PGE 2 ), leukotriene B4 (LTB 4 ), and 20-hydroxyeicosatetraenoic acid in the synovial fluid macrophages. Sal decreased representative M1 marker (iNOS and CD86, etc.) expression and M1 cytokine (TNF-and IL-1 ) production, whereas it increased M2 marker (CD206 and Arg-1) expression and M2 cytokine (TGF-and IL-10) production. The injection of conditioned medium from MSU crystal-treated macrophages into the ankle joint of rats reproduced the gouty inflammation, which was attenuated by Sal. Mechanistically, down-regulation of COX-2, 5-LOX, and CYP4A in the RAW264.7 and NR8383 macrophages by Sal skewed macrophage polarization away from the M1 phenotype, and thereby prevented neutrophil migration and chondrocyte degradation with STAT1 and NF-B inactivation. Conversely, overexpression of COX-2, 5-LOX, CYP4A or STAT1, or exogenous addition of IL-1 or TNF-partially abolished these effects. Together, inhibition of COX-2, 5-LOX, and CYP4A in macrophages by Sal ameliorates MSU crystal-induced inflammation through decreasing TNF-and IL-1 production, and may serve as a novel therapeutic strategy.
K E Y W O R D Sarachidonic acid, gouty inflammation, macrophage, metabolism, salidroside
INTRODUCTIONGout is the most common inflammatory arthritis in men older than 40 years. 1 Nonsteroidal anti-inflammatory drugs (NSAIDs) are used as Abbreviations: 20-HETE, 20-hydroxyeicosatetraenoic acid; 5-LOX, 5-lipoxygenase; ADAMTS-5, a disintegrin and metalloproteinase with thrombospondin motif 5; Clod, clodronate liposome; COX-2, cyclooxygenase-2; CYP4A, cytochrome P450 4A; LTB 4 , leukotriene B 4 ; MMP-13, Matrix metalloproteinase-13; MSU, monosodium urate; NF-B, nuclear transcription factor kappa B; PGE 2 , prostaglandin E 2 ; Sal, salidroside; STAT1, signal transducers and activators of transcription 1; ZA, zoledronic acid first-line therapy to manage gouty arthritis, whereas the inevitable gastrointestinal or cardiovascular side effects restrict their utilization. 2 Newly developed anti-IL-1 drugs appear to be highly effective, but present limitations such as high cost and hematopoietic disorders. 3 Therefore, there is an urgent need to identify novel agents for gouty arthritis treatment.Gout is triggered by monosodium urate (MSU) crystal deposition in and around joints. Macrophages play a pivotal role in the initiati...